Next Article in Journal
Nutrients, Diet, and Other Factors in Prenatal Life and Bone Health in Young Adults: A Systematic Review of Longitudinal Studies
Previous Article in Journal
Effects of Dietary and Lifestyle Interventions on Liver, Clinical and Metabolic Parameters in Children and Adolescents with Non-Alcoholic Fatty Liver Disease: A Systematic Review
Open AccessArticle

High Dose Intravenous Fish Oil Reduces Inflammation—A Retrospective Tale from Two Centers

1
General Surgery Unit, Stanley Dudrick’s Memorial Hospital, 15 Tyniecka Street, 32-050 Skawina, Poland
2
Department of Gastroenterology, Metabolic Diseases, Internal Medicine and Dietetics, Poznan University of Medical Sciences, 60-001 Poznan, Poland
3
Department of Clinical Nursing, Institute of Nursing and Midwifery, Faculty of Health Care, Jagiellonian University, 30-130 Krakow, Poland
*
Author to whom correspondence should be addressed.
Nutrients 2020, 12(9), 2865; https://doi.org/10.3390/nu12092865
Received: 6 August 2020 / Revised: 9 September 2020 / Accepted: 16 September 2020 / Published: 19 September 2020
(This article belongs to the Section Clinical Nutrition)
Aim: Patients on parenteral nutrition (PN) are prone to inflammation. This may aggravate an existing proinflammatory state and become a critical factor in the development of liver dysfunction (LD). Intravenous fish oil may attenuate this inflammatory state, but data on its use in adults are scarce. The aim of this study was to investigate the effects of adding a pure fish oil intravenous lipid emulsion (ILE) into short- and long-term PN in patients either at risk of, or with existing, inflammation. Methods: A retrospective analysis of 61 patients (32 female, 29 male, mean age 51.5 ± 12.6 years) who received all-in-one PN, including amino acids, glucose, and lipids supplemented with pure fish oil ILE, was performed. Pure fish oil ILE (Omegaven®, Fresenius Kabi, Bad Homburg, Germany) was used along with the standard ILE to reach a fish oil dose of 0.4–0.5 g fish oil/kg/d. Diagnoses were chronic intestinal failure (CIF, n = 20), Crohn’s disease (CD, n = 22), and ulcerative colitis (UC, n = 19). The observation period was 12 months for CIF and 21 days for UC and CD. Results: A reduction in inflammation was noticeable in all patients and became statistically significant in CD (hsCRP p < 0.0001, ESR p = 0.0034, procalcitonin p = 0.0014, Il-6 p = 0.001) and UC groups (hsCRP and ESR p < 0.0001, Il-6 p = 0.0001, TNF-α p = 0.0113). In the CIF group, the total bilirubin concentration (p = 0.2157) and aspartate transaminase SGOT (p = 0.1785) did not vary over time. Conclusions: PN with pure fish oil ILE reduces some inflammatory parameters in IBD and maintains liver function parameters in CIF patients. Fish oil might become a valuable ingredient in both short- and long-term PN in patients at risk of liver dysfunction. View Full-Text
Keywords: lipid emulsions; fish oil; omega-3 PUFA; omega-3 fatty acids; parenteral nutrition lipid emulsions; fish oil; omega-3 PUFA; omega-3 fatty acids; parenteral nutrition
MDPI and ACS Style

Klek, S.; Mankowska-Wierzbicka, D.; Scislo, L.; Walewska, E.; Pietka, M.; Szczepanek, K. High Dose Intravenous Fish Oil Reduces Inflammation—A Retrospective Tale from Two Centers. Nutrients 2020, 12, 2865.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop